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RESUMEN
El acido docosahexaenoico (DHA), un acido graso
esencial para la adecuada función de las células neuro-
nales: su efecto en los desordenes del comportamiento.
El cerebro y el sistema nervioso son tejidos con un alto
contenido de dos ácidos grasos poliinsaturados: el ácido
araquidónico (20:4, omega-6, AA) y el ácido docosahexae-
noico (22:6, omega-3, DHA). A pesar de la abundancia de
estos ácidos grasos en dichos tejidos los mamíferos no los
pueden sintetizar de novo. Sin embargo, la concentración de
estos ácidos grasos puede ser modificada por la dieta. El AA
y el DHA pueden ser aportados por la dieta como tales (pre-
formados) o a partir de los respectivos precursores de origen
vegetal. El ácido linoleico, precursor del AA es muy abun-
dante en la dieta occidental, por lo cual la formación de AA
no es restrictiva. Por el contrario, el ácido alfa linolénico, cual
es el precursor del DHA, es mucho menos disponible a par-
tir de nuestra dieta, siendo muy restringido el consumo de
este ácido graso en algunas poblaciones. El desarrollo del
sistema nervioso ocurre de forma excepcionalmente rápida
durante la última etapa del período gestacional y durante la
primera etapa del período post natal. En estas etapas se re-
quieren importantes cantidades de ácidos grasos poliinsatu-
rados omega-6 y omega-3, particularmente de DHA, ya que
estos ácidos grasos son críticos para el crecimiento neuro-
nal y para el desarrollo y función del cerebro y la retina. En
esta revisión se analizan varias funciones del DHA en el sis-
tema nervioso, su metabolismo en los fosfolípidos y su fun-
ción en diferentes desordenes neurológicos y del comporta-
miento, tales como la enfermedad de Alzheimer, diferentes
formas de depresión, y otras.
PALABRAS–CLAVE: Acido docosahexaenoico – Desor-
denes del comportamiento – Fosfolípidos cerebrales – Fun-
ción neuronal.
SUMMARY
Docosahexaenoic acid (DHA), an essential fatty acid
for the proper functioning of neuronal cells: their role in
mood disorders.
The brain and the nervous system are tissues with high
contents of two polyunsaturated fatty acids: arachidonic acid
(20:4, omega-6, AA) and docosahexaenoic acid (22:6,
omega-3, DHA). Despite their abundance in these tissues,
AA and DHA cannot be re-synthesized in mammals.
However, the concentration of these fatty acids can be
modulated by dietary intake. AA and DHA must be provided
by the diet as such (preformed) or through the respective
omega-6 and omega-3 precursors from vegetable origin.
Linoleic acid, the precursor of AA is very abundant in the
western diet and therefore the formation of AA from linoleic
acid is not restrictive. On the other hand, alpha linolenic acid,
the precursor of DHA is less available in our diet and
preformed DHA is highly restrictive in some populations.
During the last period of gestation and during the early post
natal period, neurodevelopment occurs exceptionally quickly,
and significant amounts of omega-6 and omega-3
polyunsaturated fatty acids, especially DHA, are critical to
allow neurite outgrowth and the proper brain and retina
development and function. In this review various functions of
DHA in the nervous system, its metabolism into
phospholipids, and its involvement in different neurological
and mood disorders, such as Alzheimer’s disease,
depression, and others are revised.
KEY-WORDS: Brain phospholipids – Docosahexaenoic
acid – Mood disorders – Neural function.
1. INTRODUCTION
During the last trimester of intrauterine foetal life
and the first 2 years of childhood, the brain undergoes
a period of rapid growth and development which has
been defined as the “brain growth spurt” (McCann &
Ames, 2005). Research over the last 30 years has
established that long-chain omega-6 and omega-3
polyunsaturated fatty acids (LC-PUFAs) are critical for
the development and functioning of the brain and
nervous system and for the proper growth and
development of newborns and children (Uauy &
Valenzuela, 2000; Wainwright, 2002; Valenzuela et
al., 2006). Brain growth spurt is associated with a
rapid increase in the incorporation of LC-PUFAs into
phospholipids that form the brain cortex. The brain
and nervous system, the retina and the sperm have
the highest concentration of the omega-3 LC-PUFA
docosahexaenoic acid (22:6, DHA), the most highly
polyunsaturated fatty acid found in mammals. In the
retina, a tissue, which from the phylogenetic point of
view can be considered of neural origin (Jeffrey et al.,
2001), DHA, is concentrated in the outer segments of
photoreceptors, in which nearly 50% of the fatty acid
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is associated with the phospholipids of these cells
(Fliesler & Anderson, 1983). In neurons, DHA is
mainly associated with membrane phospholipids
where they affect membrane fluidity and regulate the
function of many functional membrane-associated
proteins (Rapoport, 2001). DHA, when liberated from
membrane phospholipids by specific phospholipases,
may act as a regulatory molecule, as nuclear receptor
ligand or can be converted into other signalling
molecules, collectively known as docosanoids such
as docosatrienes, and the tri-hydroxy-containing
autacoids resolvins (Hong et al., 2003; Serhan &
Chiang, 2004).This conversion occurs not in neuronal
cells but in brain glial cells (Hong et al., 2003). The
novel endogenous DHA-derived 10, 17 S-
docosatriene, formed via a 15-lipooxygenase-like
enzyme and identified as neuroprotectin D1, is a
potent regulator of an intrinsic neuroprotective, anti-
inflammatory and antiapoptotic gene-expression
program that promotes survival in a stressed human
brain (Lukiw et al., 2005; Lukiw & Bazan, 2006).
It is well known that a nutritional deficiency in
omega-6 essential fatty acids in humans may
results in several pathological abnormalities such
as reduced growth, skin lesion, fatty liver, and
reproductive failure (Holman, 1998). However,
neuronal functioning appears not to be affected by
nutritional omega-6 fatty acid deficiency. On the
other hand, a nutritional deficiency in omega-3 fatty
acids results in several neuronal specific effects
such as reduced learning capacity, memory
impairment, abnormal electroretinogram, impaired
vision and numbness (Connor et al., 1992; Benatti
et al., 2004). The different pathological defects that
occur with either omega-6 or omega-3 fatty acid
deficiency demonstrated that these two types of
fatty acids are not metabolically interchangeable;
omega-6 cannot substitute omega-3 fatty acids or
vice-versa. Mammals cannot transform omega-6
fatty acids into omega-3 fatty acids (Kang, 2005).
Most of the experimental research about omega-
6/omega-3 fatty acid deficiency has been focussed
on the consequences of omega-3 deficiency,
because omega-6 deficiency in humans is
extremely rare. The western diet provides sufficient
amounts of omega-6 fatty acids but very low
amounts of omega-3 fatty acids (Simopoulos, 2002)
because preformed DHA is scarce in some
populations.
2. DHA IN THE BRAIN AND NERVOUS SYSTEM
Within neurons, DHA is highly concentrated 
in membrane phospholipids, mainly as
phosphatidylethanolamine and phosphatidylserine,
the latter being the major acidic phospholipid in
brain cell membranes (Breckenridge et al., 1972).
Phospholipids which make up about one quarter of
the solid matter in the brain are also an integral part
of the vascular system on which brain function and
nutrition depend. DHA makes up 15-20% of the
fatty acid composition of the brain cortex, and when
incorporated into phospholipids may improve the
efficiency of synaptic membrane vesicles in fusion
events which are fundamental for neurotransmission
(Salem et al., 2001). DHA may also function in
synaptic signalling either as a free fatty acid, as a
metabolite or incorporated into phospholipids. DHA
is also highly concentrated in growth cones during
neurite outgrowth where it may be important for
maximal neurite growth during brain development
which occurs mainly during the perinatal period
(Martin & Bazan, 1992). In the adult, DHA is found
in neuronal dendrites, where it may be involved in
the extension and establishment of the dendritic
arborization which occurs during memory formation
and the acquisition of learning capacities,
modifications which originate in brain plasticity.
Additionally, DHA may be important for the efficient
regeneration of axons and dendrites in some brain
regions, such as the cerebellum and hippocampus,
after neuronal injury. Supplementing cultured
neuronal cell types with AA and DHA at low
concentrations significantly increases neurite
outgrowth in several neuronal cell types, principally
those from hippocampus (Calderon & Kim, 2004).
However, there is a limit to the amount of AA to be
added because at higher concentrations this fatty
acid is cytotoxic. DHA, however, shows stimulant
effects and no cytotoxicity in a wide range of
concentrations (Ikemoto et al., 1997).
2.1. The role of DHA in neuronal phospholipid
synthesis
DHA appears to enhance neurite outgrowth by
several mechanisms which include an increase in the
synthesis of specific phospholipids (Calderon & Kim,
2004). In differentiating and mature neurons DHA is
preferentially incorporated into phospholipids rather
than into triglycerides. During the synthesis of
neuronal phospholipids, DHA is acylated to the sn-2
position of phospholipids to generate phosphatidic
acid, which is the precursor of phosphatidylinositol.
However, most of the phosphatidic acid is
subsequently dephosphorylated to generate
diacylgycerol, which is further metabolized into
phosphaditidylcholine, phosphatidylethanolamine,
phosphatidylserine and triglycerides, all of these
molecules containing DHA specifically at the sn-2
position (Calderon & Kim, 2004). Therefore, it
appears that diacylglycerols containing DHA at the
sn-2 position are preferentially transformed into
phospholipids. This specific transformation occurs
through the action of specific enzymes. For example,
diacylglycerol molecules that contain DHA in the sn-
2 position are the preferred substrate of enzyme
ethanolamine phosphotransferase which converts
diacylglycerol to phosphatidylethanolamine through
the covalent linking of ethanolamine to the sn-3
position of diacylglycerol (Holub, 1978).
Subsequently, phosphatidylethanolamine can be
converted to phosphatidylserine through the
exchange of the nitrogen base with free serine
(Mozzi et al., 2003).
204 GRASAS Y ACEITES, 60 (2), ABRIL-JUNIO, 203-212, 2009, ISSN: 0017-3495, DOI: 10.3989/gya.085208
A. VALENZUELA B
Every cell type typically maintains a constant ratio
of phospholipid species and a change in one species
of phospholipids into another may often alter the level
of another species (Araki & Wurtman, 1998). In
neurons, the bulk of DHA is incorporated into
phosphatidylethanolamine and to a lesser extent to
phosphatidylserine. On the other hand, the majority
of AA is incorporated into phosphatidylinositol 
and phosphatidylethanolamine. The bulk of other
unsaturated fatty acids, such as oleic acid, 
is incorporated mainly into phosphatidylinositol.
The differential incorporation of AA and DHA 
into phosphatidylinositol, phosphatidylserine and
phosphatidylethanolamine, compared with
phosphatidylcholine, may make an important
contribution to their specific functions in neurons.The
exact mode of action of DHA-containing
phospholipids in brain functions is at present not
known but there might be a relationship between
their effect on the blood-brain barrier, membrane
structure and fluidity in the activity of some specific
enzymes, neural signalling, ionic channel
permeability or the formation and control of nerve
growth factors (Kitajka et al., 2002). All these effects
may be involved in the brain’s cognitive functions
such as memory and learning.
2.2. The role of DHA in membrane neuronal
function
The quantity of double bonds in a fatty acid is
directly related to the flexibility of the molecule.
Saturated fatty acids, such as palmitic acid (16:0) or
stearic acid (18:0), are rigid. This rigidity allows
saturated fatty acids to pack together tightly and form
a solid structure at lower temperatures.
Phospholipids formed by these fatty acids are also
rigid structures.The introduction of double bonds into
a fatty acid causes a “kink” in its structure which
modifies its spatial conformation. DHA, which has six
double bonds, may adopt many countless
conformations because the molecule can rotate
around C-C bonds but not around the rigid six C  C
that conform its high polyunsaturation (Feller et al.,
2002). The highly flexible structure of DHA will not
allow phospholipids containing DHA to pack tightly
together, resulting in a significant increase in
membrane fluidity relative to phospholipids formed
only by saturated fatty acids. Membranes having high
contents of DHA may also increase the efficiency of
membrane fusion events which are important in
neurotransmission (Teague et al., 2002). Additionally,
an increased fluidity of membranes appears to be
important for increasing the rate at which membrane
protein-protein interaction occurs within the
phospholipid’s membrane bilayer. Fluidity is
especially relevant in the outer segments of retinal
photoreceptors where the activation of G type protein
transducin by the rhodopsin-metarhodopsin
interaction events occurs within the phospholipids of
photoreceptor cells. This process does not occur
efficiently when the level of DHA in the phospholipids
of vision cells is reduced either during normal ageing
or by pathological causes (Niu et al., 2004).
Mitochondrial phospholipids are also enriched in
DHA. High DHA in mitochondrial membranes may
increase the efficiency of the electron transport chain
and the ADP-phosphorilation process by increasing
the lateral movement of proteins within the
membrane bilayer, thus facilitating protein-protein
interactions (Valentine & Valentine, 2004).
Additionally, there is a direct correlation between the
DHA content of mitochondrial phospholipids and the
permeability of the inner membrane to protons
(Hulbert, 2003), thus improving the efficiency of
energy production through oxidative phosphorilation.
It is generally concluded that DHA positively
influences mitochondrial energy function.
2.3. DHA and the activity of neuronal enzymes
Receptor functioning and the activation of
proteins involved in neuronal signalling transduction
can be influenced by DHA, either as a free fatty acid
and/or when it is incorporated into membrane
phospholipids. DHA is concentrated in the
phospholipids of neural tissues, including the
hippocampus (Ahmad et al., 2002) which is involved
in learning as well as in memory storage. Recently,
we demonstrated that DHA supplementation to
mother rats during the perinatal period, increases the
DHA content of different brain segments of the pups,
including hippocampus, and improves the learning
and memory capacities of the pups when evaluated
through the Skinner box test (Valenzuela et al.,
2008). As part of the diacylglycerol molecule, DHA
enhances the diacylglycerol-dependent activation of
the protein kinase C (PKC) (Chen & Murakami,
1994). It is interesting that PKC has an essential
requirement for phosphatidylserine (Nishizuka,
1995), which contains a high concentration of DHA.
However, in vitro evidence is suggesting that
unesterified DHA may competitively inhibit
phosphatidylserine dependent PKC activation.
Unesterified AA either stimulates or has no effect on
PKC activity (Seung Kim et al., 2001), showing that
activation of the enzyme by omega-3 fatty acids may
be specific to these fatty acids. Another example of a
protein whose function is modified by DHA is Na,
K ATPase, also known as sodium pump, which is
an integral protein of the neuronal membrane found
in higher concentration at the axonal nodes of
Ranvier. The primary neuronal function of this
ATPase is to generate and maintain Na and K
gradients necessary to maintain the resting potential
of neuronal membrane. The activity of Na-K
ATPase is increased in the sciatic nerve of rats that
are supplemented with DHA (Gerbi et al., 1998).
2.4. Inhibition of neuronal apoptosis by DHA
Neuronal cell survival is highly dependent on the
presence of trophic nerve factors which influence
downstream signalling pathways. Modifications in the
GRASAS Y ACEITES, 60 (2), ABRIL-JUNIO, 203-212, 2009, ISSN: 0017-3495, DOI: 10.3989/gya.085208 205
DOCOSAHEXAENOIC ACID (DHA), AN ESSENTIAL FATTY ACID FOR THE PROPER FUNCTIONING…
concentration and/or number of these factors may
lead to apoptotic cell death. Early signs of apoptosis
include the loss of intracellular water, an increase in
cytoplasmic calcium concentration, the releasing of
cytochrome c from mitochondria and the
translocation of phosphatidylserine to the outer leaflet
of the plasma membrane (Sastry & Rao, 2000). The
activation of the caspase-3 enzyme by self-cleavage
results in the death of cells by apoptosis (Nagata,
1997). The prevention of apoptosis by DHA
incorporation into phospholipids has been reported
for rat retinal photoreceptors (Rotstein et al., 1997),
HL-60 cells (Kishida et al., 998), and Neuro 2A cells
(Kim et al., 2000). Additionally, an increased dietary
intake of DHA prevents apoptosis in mouse retinal
photoreceptors when subjected to N-methyl-N-
nitrosourea, a potent inducer of apoptosis (Moriguchi
et al., 2003). DHA accumulation in phospholipids,
mainly in phosphatidylserine, appears to promote
neuronal survival under adverse conditions (Kim et
al., 2000).
As discussed above, in the nervous system,
DHA is incorporated primarily into anionic
phospholipids such as phosphatidylserine and
phosphatidylethanolamine (Aid et al., 2003).
Phosphatidylserine is synthesized from
phosphatidylethanolamine or phosphatidylcholine
by the serine replacement of ethanolamine or
choline, respectively, in a base-exchange reaction.
Phosphatidylserine is involved in a series of cell-
signaling events. The supplementation of cells with
unesterified DHA promotes phosphatidylserine
biosynthesis (Kim & Hamilton, 2000). The
enrichment of DHA in phosphatidylserine and its
effect on phosphatidylserine biosynthesis are most
likely due to the fact that phospholipid species
containing DHA are the best substrates for
phosphatidylserine synthesizing enzymes (Kim et
al., 2004). There is not a direct correlation between
the level of phosphatidylserine and DHA content in
different brain segments. The antiapoptotic effect of
DHA in neurons occurs only when the fatty acid is
added to cultured cells or when experimental
animals have been treated previously with DHA,
which may suggest that these effects are due to the
incorporation of DHA into different phospholipids. It
is interesting to note that in other non-neuronal cell
types, DHA actually promotes apoptosis. For
example, in CaCo-2 cells, a colon cancer cell line,
DHA induces apoptosis by “downregulating”
reducing the expression of antiapoptotic genes and
increasing the expression of proapoptotic genes
(Narayanan et al., 2001). Therefore, the
antiapoptotic effects of DHA-containing
phosphatidylserine are probably specific to
neuronal cells and critical for the long-term survival
of these cells.
2.5. DHA and the regulation of gene
expression in neurons
It has been demonstrated that polyunsaturated
omega-3 fatty acids can modify gene expression by
binding to specific receptors and transcription
factors in the liver and adipose tissue. Receptors
activated by DHA include retinoid X, peroxisome
proliferator activated receptors (PPARs), hepatic
nuclear receptor, and sterol regulatory element
binding protein (SREBP) receptor (Mata de Urquiza
et al., 2000). The activation of each of these
proteins modulates the expression of genes
involved in the metabolism of glucose, fatty acid,
triglyceride, and cholesterol. Of these proteins, the
retinoid X receptor is present in significant levels in
the brain, and DHA is an effective ligand and
activator of the retinoid X receptor protein
(Lengqvist et al., 2004). Activation of gene
expression by DHA is not restricted to brain cells,
the fatty acid activates several genes in other
tissues, like liver or adipose tissue (Kitajka et al.,
2002). In rat brain cells, the stimulation of
peroxisomal proliferator activated receptor β (PPAR
β) and resulted in the upregulation of the mRNA
encoding a protein that converted DHA to the acyl-
CoA derivative (Marszalek et al., 2005). Upon
alteration of the expression of genes involved in
lipid metabolism, the optimal environment for
neurite outgrowth can be achieved during neuronal
differentiation and brain formation. For example,
omega-6 and omega-3 PUFAs have been shown to
decrease the expression and the activity of ∆-9
desaturase, the enzyme that converts estearic acid
(18:0) to oleic acid (18:1, omega-9) (Sessler et al.,
1996). This effect may be important to ensure that
saturated fatty acids, whether newly synthesized or
taken in from the diet, are available for the insertion
of phospholipids into the sn-1 position as they are
synthesized. Several studies have demonstrated
that the DHA increasing effect on neurite outgrowth
may be, in part, a consequence of the DHA
stimulation of the expression of genes that promote
phospholipids synthesis (Barcelo-Coblijn, 2003;
Puskas et al., 2003). Using microarray gene
expression methodology, it has been demonstrated
that fish oil or DHA supplementation can modify the
expression of many of the genes of the brain and
retina involved in signal transduction, eicosanoid
production, synaptic plasticity, and energy
metabolism in rats (Rojas et al., 2003).
3. DHA AND ALTERATIONS OF NEURONAL
FUNCTIONING AND MOOD DISORDERS
During periods of nutritional deficiency of
omega-3 fatty acid, DHA is retained to depletion
from the phospholipids of neurons through at least
two different mechanisms. First, DHA released from
membrane phospholipids is rapidly reacylated to
specific phospholipids. Second, there is a
significant reduction in the rate of transfer of DHA
out of the nervous system through the blood-brain-
barrier. Many neurodegenerative conditions, such
as Alzheimer’s disease, retinal affections, and some
peroxisomal disorders (Zellweger syndrome and
adrenoleucodisthrophy) are associated with
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reduced levels of omega-3 fatty acids. Mood
disorders, such as depression, schizophrenia, and
post partum depression, have also been associated
with modifications in DHA metabolism.
Epidemiological, experimental and clinical data
favour the hypothesis that DHA could play a role in
the pathogenesis and eventually in the treatment of
these diseases (Parker et al., 2006; Stahl et al.,
2008).
3.1. Alzheimer’s disease
Alzheimer’s disease is a late-onset, progressive,
neurodegenerative disease of heterogeneous origin
which is devastating both to the afflicted person and
to that person’s family. The pathology is
characterized by the formation of amyloid plaques,
neurofibrillary tangles, and dystrophic neurites.
Data from numerous epidemiological studies
suggest an inverse correlation between DHA intake
and the likelihood of developing Alzheimer’s
disease. A reduction in the level of total
phospholipids as well as a decrease in DHA has
been described in various cerebral areas in
Alzheimer’s disease patients (Prasad et al., 1998).
Studies have demonstrated that the levels of
phosphatidylethanolamine, which is enriched in
DHA, and of phosphatidylinositol, which is enriched
in AA, are significantly reduced in the brain of
individuals affected by Alzheimer’s disease.
Specifically, there is a significant reduction in the
amount of DHA in the frontal cortex and
hippocampus phospholipids of patients with
Alzheimer’s disesase (Soderberg et al., 1991). The
pretreatment of rats with DHA protected the
animals against the memory loss which typically
occurs when they are infused with Alzheimer
disease Aβ peptide, which triggers a synapse loss
(Coleman & Yao, 2003). DHA inhibits the
accumulation of insoluble Aβ peptide, partially by
decreasing cholesterol levels in the detergent
insoluble membrane domains (rafts) of the cerebral
cortex (Hashimoto et al., 2005). It has been recently
demonstrated that the effect of DHA in the
reduction of insoluble Aβ peptide is attributable to a
decrease in the steady-state levels of presenilin 1
(Green, et al., 2007). In cognitive tests, animals
expressing high levels of a mutant amyloid
precursor protein, showed low levels of DHA in
brain phospholipids. Additionally, the activity of
phospholipase A2, which is involved in the
liberation of AA from brain phospholipids, increases
in the brain of patients with Alzheimer’s disease,
suggesting that an increased generation of AA-
derived eicosanoids, which are antagonist of DHA-
derived docosanoids, may contribute to the
aetiology of Alzheimer’s disease. It has been
proposed that DHA-derived neuroprotectin induces
an antiapoptotic and neuroprotective gene-
expression program that regulates the secretion of
Aβ peptide, resulting in the modulation of
inflammatory signalling, neuronal survival, and the
preservation of brain cell function (Lukiw et al.,
2005). The typical Western diet provides <30% of
the 200-300 mg/day of DHA recommended by
Expert Panels. Epidemiology shows a risk reduction
of 60% associated with a modest increase in DHA
intake or plasma levels. DHA works well in slowing
down Alzheimer’s disease pathogenesis in mice
with a human Alzheimer’s disease gene (Calon et
al., 2004). DHA provided by supplementation (e.g.
fish meals, fish oil capsules, or other forms of DHA
supplementation), could restore DHA deficiency in
membrane phospholipids in the cerebral cortex of
patients with Alzheimer’s disease (Connor &
Connor, 2007). DHA, together with natural
antioxidants, may exert general anti-Alzheimer’s
and anti-aging benefits (Cole et al., 2005).
3.2. Depression and postpartum depression
Depression is a complex disorder that
particularly involves neurotransmission processes,
especially serotonin receptors and membrane
transporters (Meltzer, 1990). The aetiology of the
illness is multi factorial, influenced by genetic,
environmental, and nutritional factors. Support for a
nutritional contribution to the disease derives from
studies that report an inverse correlation between
the level of omega-3 fatty acids (DHA and/or EPA),
as measured in either red blood cell phospholipids
or adipose tissue, and symptoms of depression
(Freeman et al., 2006). An increased ratio of
omega-6/omega-3 is frequently observed in
patients suffering from depression (Peet et al.,
1998; Haag, 2003). Numerous studies carried out
over the last few years are involving omega-3 LC-
PUFA supplementation with the reduction of many
of the symptoms of different forms of depression,
including bipolar disorders, postpartum depression
(discussed forward), agoraphobia, and anorexia
nervosa (Locke & Stoll, 2001; Logan, 2004). EPA
supplementation appears to be more effective than
DHA supplementation in reducing the symptoms of
depression as concluded from a recent meta-
analysis (Lin & Su, 2007). Depression and coronary
artery disease often occur in the same individuals
who frequently have low plasma levels of EPA and
DHA and high levels of AA. Omega-3 LC-PUFA
supplementation is effective in the prevention of
these pathological disorders (Frasure-Smith et al.,
2004; Astog et al., 2008). However, the
mechanism(s) by which EPA and/or DHA may
reduce depression are still unclear, and more
research is needed. As discussed, increasing the
nutritional levels of omega-3 fatty acids may modify
the activity of integral membrane proteins
(receptors, ion channel, molecular pups, etc),
and/or counteract the proinflammatory action of AA-
derived eicosanoids.
Depression during pregnancy and postpartum
depression have negative impacts on the
development and health of the newborn. Maternal
stress in humans is associated with foetal hypoxia,
reduced gestational age, and low birth weight
(Wadhwa et al., 1993). Evans et al (2001) found that
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13.5% of women (n  14,541) experienced serious
symptoms of depression during pregnancy and
postpartum. A cross-national analysis of seafood
consumption, and the DHA content of breast milk,
demonstrated an inverse correlation with the
prevalence of pregnancy and postpartum
depression. The prevalence varied from 0.5% in
Singapore to 24.5% in South Africa, with a mean
prevalence rate worldwide of 12.4%. Both higher
national seafood consumption and higher DHA
content in the mother’s breast milk predicted a lower
prevalence of postpartum depression. The mean
DHA intake of western women is estimated at 15-20
mg/day, whereas intake in countries with high fish
consumption (e.g. Japan, Korea, and Norway) is
approximately 1000 mg/day. During the third
gestational trimester, the foetus accumulates an
average of 67 mg/day of DHA, in excess of the
dietary intake of many women. Such transfer to the
baby through the placenta and, subsequently
through breast milk poses a risk to women of
significant depletion of omega-3 fatty acids during
pregnancy and lactation, thus contributing to the
perinatal risk of depression. A review by Parker et al.,
(2006) about omega-3 fatty acids and postpartum
depression, proposed that DHA supplementation in
the perinatal period may have additional benefits for
the infant’s neurodevelopment. Women and their
physicians prefer options to standard antidepressant
medication during pregnancy and postpartum. DHA
supplementation during these periods may be a
plausible alternative (Freeman et al., 2006).
However, more clinical trials are needed to confirm
the recommendation of omega-3 fatty acid
supplementation to avoid or reduce symptoms of
depression.
3.3. Schizophrenia
Schizophrenia is a psychiatric disease that
affects ~1% of the population with a higher
prevalence in males than in females. The
predominant hypothesis regarding the
pathophysiology of the disease is dysfunction of the
dopaminergic system. However, further findings
concerning the disease suggested a close
relationship with reduced tissue levels of omega-6
and omega-3 fatty specially AA and DHA (Yao et
al., 2000). Several mechanisms could explain these
deficits, including an increased activity of
phospholipase A2 thus inducing the extraction of
AA and DHA from cerebral membranes (Horrobin
et al., 1994). Another argument in favour of a
relationship between schizophrenia and omega-
6/omega-3 fatty acids is that dietary
supplementation of either AA and DHA or their
precursors is able to alleviate symptoms of the
disease (Arvindakshan et al., 2003). It has been
recently proposed that an alteration of DHA
metabolism in the brain is involved in the
pathophysiology of schizophrenia and that omega-
3 fatty acid supplementation may be an important
coadjutant in the treatment of the disease (Kale et
al., 2008). It seems therefore that schizophrenia
might be an example of a disease in which omega-
6 and omega-3 supplementation, presumably AA
and DHA, associated with pharmacological
treatment might be beneficial, although extended
evaluation of such treatment is still required (Fenton
et al., 2000).
3.4. Retinal function
Retinal pathologies are not directly involved with
mood disorders. However, the retina has neural
origin and DHA is essential for the proper
development and functioning of this tissue,
particularly at the outer membrane segments of
photoreceptors cells. DHA is required for the
survival of retinal photoreceptors and exerts a
protective effect on apoptosis of these
photoreceptors during development (Kim et al.,
2000). Retinitis pigmentosa is a visual disease with
a worldwide prevalence of about 1 in 4000 persons
(Boughman et al., 1980). A correlation between
retinitis pigmentosa and low retinal DHA levels has
been observed, were there is some evidence that
the synthesis of DHA is impaired in patients
suffering from X-linked retinitis pigmentosa (Kim et
al, 2000). Supplementation with DHA (400 mg/day)
for four years produced a significant a reduction in
the loss of the functionality of rods in patients with
retinitis pigmentosa, as assessed by an
electroretinogram which measures photoreceptor
functioning. For patients with retinitis pigmentosa
beginning vitamin A therapy, along with DHA (1200
mg/day) slowed the course of the decline in visual
field sensitivity (Berson et al., 2004). These results
suggest that early intervention with omega-3 fatty
acids, presumably with DHA, may be important in
slowing down the progression of retinitis
pigmentosa.
4. POSSIBLE MECHANISMS FOR LINKS
BETWEEN DHA AND MOOD DISORDERS
Several neurophysiological mechanisms have
been proposed to explain the relationship between
omega-3 polyunsaturated fatty acids and mood
disorders (Mamalakis et al., 2002). EPA and DHA
appear to decrease the production of inflammatory
eicosanoids from AA by means of two mechanisms:
First, they compete with AA for incorporation into
membrane phospholipids, thus decreasing both
cellular and plasma levels of AA. Second, EPA and
presumably DHA compete with AA for the cyclo-
oxygenase enzyme system, inhibiting the
production of proinflammatory eicosanoids derived
from AA (e.g. prostaglandins, leukotrienes,
hromboxanes). Prostaglandin E2 and thromboxane
B2 have been linked to depression. DHA also
inhibits the release of proinflammatory cytokines
such as interleukin-1 beta, interleukin-2, interleukin-
6, interferon gamma, and tumor necrosis factor
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alpha which depends on eicosanoid release and
are also associated with mood disorders, such as
depression (Logan, 2003). Another possible
mechanism relates to the abundance of DHA in
brain phospholipids were they play a vital role in
maintaining the integrity and fluidity of neuronal
membranes. By varying the lipid concentration in
cell membranes, changes in fluidity can affect either
the structure or functioning of proteins embedded in
the membrane, including enzymes, receptors or ion
channels, leading to changes in cellular signalling
(Yehuda et al., 1998; Stahl et al., 2008). Support for
the involvement of DHA in receptor functioning,
neurotransmitter levels and the metabolism of
monoamines implicated in mood disorders has
been provided by animal studies (Hibbeln & Salem,
1995).
The hypothesis that DHA can affect membrane
fluidity is supported by a recent study using
magnetic resonance imaging (Hirashima et al.,
2004). A group of bipolar women received DHA for
4 weeks and were contrasted with a non treated
bipolar group. T2 whole relaxation times were used
to detect changes in membrane fluidity, measured
at baseline and 4 weeks after omega-3 fatty acid
treatment. The bipolar patients receiving DHA
treatment showed significantly decreased T2
values, with a dose-dependent effect compared to
the control group. Another hypothesis involves a
more direct mechanism controlling gene expression
and the binding of fatty acids to specific nuclear
receptors early in life, as was discussed above,
leading to genetic transcription and predisposure to
a range of diseases related to DHA depletion later
in life, such as Alzheimer’s disease, cardiac
disease, and depression (Sampath & Ntambi,
2004).
5. CONCLUSIONS AND FUTURE PROSPECTS
A significantly amount of references clearly
establish that DHA is important for the proper
neurodevelopment of the brain and visual system.
Epidemiological evidence suggest that a decrease
in brain DHA levels, which normally occurs during
aging, and that is exacerbated by reduced dietary
intake of DHA, may increase the prevalence of
several neurological diseases, such as Alzheimer’s
disease. However, at present we do not understood
at all the complex functions that DHA performs as
either a free fatty acid or incorporated into
phospholipids. Further research is needed to better
understand the process of DHA transport,
internalization and membrane inclusion, as well as
DHA metabolism into its incorporation into
phospholipids. The identification of several DHA-
derived metabolites, probably involved in cell
signalling suggests that free DHA is utilized to
perform many functions beyond a structural role in
phospholipids and membrane structure. Future
research about food and/or additives that
preferentially provide DHA and molecules that
promote its internalization, transport and
metabolism is clearly needed to fully understand
the importance of DHA in the development, normal
function, senescence, and pathology of the nervous
system. Establishing the functions of DHA in the
nervous system will be critical to appreciating the
possible health implications of a reduced dietary
intake of DHA currently occurring in western
populations, and the importance of DHA
supplementation, at the early and late stages of
human life. Basic, clinical and epidemiologic
research supports a protective effect of omega-3
LC-PUFA, particularly of DHA in mood disorders.
However, results are highly heterogeneous and in
some cases confounding, indicating that it is
important to examine the results of each individual
study in order to anticipate more general
conclusions about the role of DHA in the brain and
nervous system and in mood disorders.
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